ClinicalTrials.gg
Not yet recruitingNCT06589141Updated Sep 19, 2024

Comparison Between Metformin and Glyburide in the Management of Gestational Diabetes

An interventional study of MetFORMIN 500 Mg Oral Tablet and GlyBURIDE 2.5 MG Oral Tablet in Gestational Diabetes Mellitus in Pregnancy, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Assiut University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 39 studies testing metformin in Diabetes, Gestational — 4 open to participants now, 5 under way, none of them phase 3. Metformin · Diabetes, Gestational.

Planned enrollment
12th of 39
180 · median 112
Started
2025
with 1 other
No phase
6 of 39
1 open now
Registered
38th of 39
by date
Lead sponsor
1 of 39
Assiut University

Among the 39 studies testing metformin in Diabetes, Gestational, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 with no phase, and was the 38th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 39 studies testing metformin in Diabetes, Gestational are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing metformin in Diabetes, Gestational, or all of them as a file.
02

Study summary

This study aims to compare the maternal, fetal, and neonatal outcomes associated with the use of metformin versus glyburide for managing gestational diabetes.

The objective is to assess the safety and effectiveness profiles of both medications as potential alternatives to initiating insulin therapy.

Read the detailed description

Primary Outcome: treatment failure is defined as the initiation of insulin due to failure of glycemic control (more than 10% of high values using 4-point glucose checks) or side effects.

Secondary Outcomes:

Maternal:

  • Percentage of fasting and postprandial glucose levels within target levels after initiation of treatment
  • Incidence of maternal hypoglycemia
  • Reported maternal side effects
  • Maternal weight gain
  • Preterm delivery
  • Development of pregnancy-induced hypertension
  • Labor dystocia.
  • Instrumental delivery and its indication (fetal compromise, delay in progress, or maternal exhaustion)
  • Mode of delivery
  • Incidence of third and fourth perineal tear

Fetal and neonatal:

  • Fetal large for gestational age
  • Intrauterine fetal death
  • Newborn weight
  • Gestational age at delivery
  • Neonatal birth injuries
  • Stillbirth and neonatal death
  • Apgar score at 1 minute
03

Conditions studied

  • Gestational Diabetes Mellitus in Pregnancy

Browse trials for

Keywords

  • Metformin and Glyburide
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women over 18 years old.
  • Gestational age between 24 - 28 weeks.
  • New diagnosis of gestational diabetes mellitus using a 2-hour glucose tolerance test.
  • Medical therapy is indicated to control blood glucose following the failure of diet and lifestyle changes to solely achieve glycemic control (A2GDM).

Exclusion criteria

Exclusion Criteria:

Patients with pre-gestational diabetes.

  • First trimester fasting blood glucose ≥105 mg/dl or > 6.4%.
  • Major fetal anomalies.
  • Intrauterine growth restriction (IUGR) before 24 weeks.
  • Abnormal renal or liver function.
  • to metformin or glyburide.
  • Medical treatment declined by the patient.
  • Direct indication to commence insulin (initial fasting blood glucose >= 7 mmol/l or 126 mg/dl or >= 6 mmol/l or 108 mg/dl with macrosomia or polyhydramnios).
  • Significant medical co-morbidities requiring continuous medical treatment in pregnancy.
  • Non-compliance to blood glucose self-monitoring (missing 50% or more of total readings)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Metformin

    Metformin (500 to 2000 mg orally)

    Drug: MetFORMIN 500 Mg Oral Tablet

  • Experimental
    Glyburide

    Glyburide (2.5 mg to 20 mg orally)

    Drug: GlyBURIDE 2.5 MG Oral Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment failure

    Initiation of insulin due to failure of glycemic control (more than 10% of high values using 4-point glucose checks) or side effects

    Time frame: From 28 weeks till 41 weeks of pregnancy

Secondary outcomes

  1. Incidence of maternal hypoglycemia

    Incidence of blood glucose levels below 4 mmol/L during the period of treatment

    Time frame: From 28 weeks till 41 weeks of pregnancy

  2. Significant side effects

    Incidence of maternal significant side effects requiring cessation of treatment (gastrointestinal side effects)

    Time frame: From 28 weeks till 41 weeks of pregnancy

  3. Fetal macrosomia (large for gestational age)

    Incidence of fetuses growing above the 90th percentile on third ultrasound scan using customised growth chart

    Time frame: 32 weeks of gestation to onset of labour

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ye W, Luo C, Huang J, Li C, Liu Z, Liu F. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2022 May 25;377:e067946. doi: 10.1136/bmj-2021-067946. PubMed 35613728 ↗
  • Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med. 2012 Jan 10;40(3):225-8. doi: 10.1515/jpm-2011-0175. PubMed 22505499 ↗
  • Shuster DL, Shireman LM, Ma X, Shen DD, Flood Nichols SK, Ahmed MS, Clark S, Caritis S, Venkataramanan R, Haas DM, Quinney SK, Haneline LS, Tita AT, Manuck TA, Thummel KE, Brown LM, Ren Z, Brown Z, Easterling TR, Hebert MF. Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus. Clin Pharmacol Ther. 2020 Jun;107(6):1362-1372. doi: 10.1002/cpt.1749. Epub 2020 Jan 25. PubMed 31869430 ↗
  • Oliveira MM, Andrade KFO, Lima GHS, Rocha TC. Metformin versus glyburide in treatment and control of gestational diabetes mellitus: a systematic review with meta-analysis. Einstein (Sao Paulo). 2022 Feb 16;20:eRW6155. doi: 10.31744/einstein_journal/2022RW6155. eCollection 2022. PubMed 35195193 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2025, 11 months later.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 11 months is below that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2024
First posted
Sep 19, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Jun 30, 2026
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06589141
Lead sponsor
Assiut University
Collaborators
Middle-Eastern College of Obstetricians and Gynecologists
Responsible party
Sherif Abdelkarim Mohammed Shazly (Senior clinical fellow, Middle-Eastern College of Obstetricians and Gynecologists) — Principal investigator
First posted
Sep 19, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Sep 19, 2024

Study contacts

Sherif Shazly, MSc
Contact
shazly.sherif2020@gmail.com
+447554480388

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Glyburide

Start the discussion